Healthcares been in the news a lot lately thanks to the Republicans efforts at healthcare reform. There are several bottoming heathcare and biotech stocks that could benefit from these efforts. One of those companies with potential is Myriad Genetics (MYGN). Myriad creates genetic tests to screen for genetic cancer risk and other diseases. Its currently coming out of a bottom and has the potential to continue moving up if it can capitalize on this growing market.
Myriad manufactures molecular diagnostic tests to screen for genetic dispositions to cancer, autoimmune diseases, and other maladies. The company is probably best known for its BRACAnalysis test. This test determines womens risk for breast cancer by detecting mutations in the BRCA1 or BRCA2 genes. Genetic mutations greatly increase the risk of developing cancer. So these type of diagnostic tests are growing more and more important for detecting cancer risks early. Advanced diagnostics also allow doctors to tailor their preventative medicine programs to better serve the patients individual needs. In fact, personalized medicine is expected to be the wave of the future. Theres also an increasing need for better diagnostic tools as the population ages. So Myriads products can fill an important niche in a growing market.
Myriads stock was in some trouble until recently. A monthly stock chart shows that MYGN was in a bear market for pretty much all of 2016. It finally started to bottom late in 2016, and completed its bottom in May of 2017. Its currently moving up strongly out of its bottom, but has retraced a bit over the past month. MYGNs all time high is at about $47, so this stock some room to move up.
Figure 1: Monthly chart of MYGN. Chart provided by FreeStockCharts.com.
A weekly chart confirms that MYGN completed its bottom last May. The chart shows very large and strong white candles coming out of the bottom, lacking indecisive wicks and tails. Small black candles form for about a month after each strong move up, likely due to profit taking. The stock is also currently undergoing some profit taking after the last strong move up in June. There have been green volume surges on the moves up, with green volume bars outnumbering the red bars since coming out of the bottom.
Figure 2: Weekly chart of MYGN. Chart provided by FreeStockCharts.com.
We can see the current retracement in more detail in the daily chart. Black candles have been larger and more numerous over the past month. We can see the strength of the green volume in May and June. But volume has been low in July, with red volume becoming more and more dominant. The chart also shows that high frequency traders (HFT) tried to sell down this stock on 7/21, possibly in response to a news release that day. It looks like the HFTs moved in at the start of the day, but failed to move the stock down much.
Figure 3: Daily chart of MYGN. Chart provided by FreeStockCharts.com
The chart indicators also confirm this weakness in the current price action. RSI is moving down steadily to the bottom of the chart. Stochastics has also moved down well into oversold territory. Both indicators look a little overextended but dont show any signs of a reversal quite yet.
Figure 4: Indicator charts for MYGN. Chart provided by FreeStockCharts.com
MYGN really looks a little week right now. There arent enough buyers to stop the slip-slide due to profit taking. The pattern of this stock, however, has been to move up strongly and then slowly slide back for a month. So well see if the stock continues that trend in August.
The charts show that MYGN has recovered nicely in 2017. So lets check the fundamentals and see if they justify the stocks uptrend. Myriads income statement shows that revenues started to turn around in the first quarter of fiscal year 2017. Revenues, however, were flat last quarter. Net income, on the other hand, has been inconsistent. Income has been up and down for the past several quarters. Costs have also continued to rise, but flattened out last quarter.
Figure 5: Income statement for MYGN. Data provided by Google Finance.
Myriad also took on a lot of debt in the second quarter of fiscal year 2017. The company started to pay down that debt last quarter, so at least its controlling its debt load. The current ratio is about 1.6, which is acceptable.
Figure 6: Balance sheet for MYGN. Data provided by Google Finance
Data from Nasdaq.com shows that the institutional holdings are above 100%. This usually means that some convertible bonds were executed, or that there was a direct stock sale to an institution. This should pattern out in the next quarter after Nasdaq.com updates its information. MYGN has 261 holders, so its pretty widely held for a small cap. And more funds started new positions or increased their positions compared to funds that sold out or decreased their holdings.
Figure 7: Institutional Holdings for MYGN. Data provided by Nasdaq.com.
A few giant funds are among the top holders of this stock, including Vanguard and Dimensional Fund Advisors. There are few giant banks in the mix as well, such as Blackrock and State Street. Some large banks have reduced their holdings in this stock though, which is interesting. The buy side institutions are doing the opposite; theyre increasing their positions or holding steady.
Figure 8: Top holders for MYGN. Data provided by Nasdaq.com.
Myriads financial performance improved last year but slowed down last quarter. Can it pick up again? A quick look at the last earnings report can show us what to expect. Myriad expects accelerating growth going forward, per CEO Mark Capone. Capone said, Coupled with meaningful sequential volume growth in all of our major pipeline tests including GeneSight, Vectra DA, Prolaris, and EndoPredict, we believe we are rapidly approaching an important inflection in our business where our new products will drive accelerated revenue growth and profitability.
That sounds promising, but we need more specifics. Luckily, the report also provides guidance for the fourth quarter of fiscal year 2017. The company expects revenues of $192-$194 million, which is flat to slightly down compared to last quarter. Earnings per share are expected in the range of $0.11 to $0.13, which is a large improvement over the $0.06 per share reported last quarter. Revenues for the full fiscal year are expected to be $763-$765, up just 1% over 2016. Earnings per share are expected to drop from 2016, down to $0.23-$0.25. This reflects the slowdown in earnings that was observed in the first three quarters of fiscal year 2017. The company needs to show that it can continue to grow revenues and earnings more consistently. Itll be interesting to see what the guidance is for 2018 in the next earnings release. Myriad is expected to report around August 8th.
MYGN has trended up fairly strongly out of its 2016 bottom. Its also in a market with a lot of potential, notwithstanding the healthcare shenanigans going on in Congress right now. The companys financials showed improvement earlier in the year, but have started to lag more recently. It needs to continue to grow revenues and earnings, otherwise the current profit taking could turn into broader selling. The 2016 high of $40 could also challenge the uptrend if the financials dont continue to improve. The stock shows some promise, but theres also some uncertainty about companys performance in the next fiscal year. The fact that large funds are interested in this stock bodes well for it though. And an earnings report that beats expectations could cause the stock to move up strongly again. Investors that are interested this companys technology should wait until the profit taking ends before entering this stock though. The $27 level looks like a good place to enter. For everyone else, its best to wait until the next earnings report to see the companys projections for fiscal year 2018.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Read more from the original source:
Myriad Genetics' Stock Is Starting To Make A Run - Seeking Alpha
- Sequence errors are canaries in a coal mine in genetics studies, sleuth says - Retraction Watch - March 30th, 2025 [March 30th, 2025]
- Significance of noninvasive prenatal testing using massively parallel sequencing in women with twin or vanishing twin pregnancies | Journal of Human... - March 30th, 2025 [March 30th, 2025]
- All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance - March 30th, 2025 [March 30th, 2025]
- 23andMe Stock Is Surging After a Bankruptcy Judge Cleared Genetics Business Sale. Heres Why You Need to Stay Far Away From ME Shares. - Barchart - March 30th, 2025 [March 30th, 2025]
- Dairy producers leverage genetics to optimize milk composition for processing - Feedstuffs - March 30th, 2025 [March 30th, 2025]
- Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance - March 30th, 2025 [March 30th, 2025]
- Human genetics and biotechnology company 23andMe to pursue bankruptcy sale after failed prepetition attempt Case Profile - ION Analytics - March 30th, 2025 [March 30th, 2025]
- AP Biology Students At NLHS Explore Genetics With Build-A-Baby Monster Lab - EastTexasRadio.com - March 30th, 2025 [March 30th, 2025]
- Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance - March 15th, 2025 [March 15th, 2025]
- Helix Unveils Groundbreaking Real-World Insights at the ACMG Annual Clinical Genetics Meeting, Driving Clinical Care Forward - PR Newswire - March 15th, 2025 [March 15th, 2025]
- S2 Episode 3: Molecular Classification and Genetics of Endometrial Cancer - Medscape - March 15th, 2025 [March 15th, 2025]
- Fowl Play: How Chicken Genetics Barons Created the Egg Crisis - The Big Newsletter - March 15th, 2025 [March 15th, 2025]
- Exposure to violence alters human genetics for future generations - Earth.com - March 5th, 2025 [March 5th, 2025]
- Family-based genetics identifies association of CUBN IL1RL1 and PRKN variants with leprosy in Bangladesh - Nature.com - March 5th, 2025 [March 5th, 2025]
- The role of genetics in infant hearing loss: What parents need to know - The Times of India - March 5th, 2025 [March 5th, 2025]
- Analyzing Genetics May Lead to Better Contraceptive Experiences for Women - Yale School of Medicine - March 5th, 2025 [March 5th, 2025]
- Fulgent Genetics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance - March 5th, 2025 [March 5th, 2025]
- Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the... - February 25th, 2025 [February 25th, 2025]
- Dual recombinase-mediated intersectional genetics defines the functional heterogeneity of neural stem cells in adult hippocampus - Nature.com - February 25th, 2025 [February 25th, 2025]
- Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - Yahoo Finance - February 25th, 2025 [February 25th, 2025]
- The Genetics of Creativity: Can Creative Talent Be Inherited? - Etownian - February 25th, 2025 [February 25th, 2025]
- Weight and metabolism determined more by genetics than diet - WVTF - February 25th, 2025 [February 25th, 2025]
- Beyond genetics: The biggest factors that influence health and aging - Earth.com - February 25th, 2025 [February 25th, 2025]
- Study finds lifestyle, environment have greater impact on lifespan than genetics - CBS Boston - February 25th, 2025 [February 25th, 2025]
- 6 Things to Know About Genetics in GI Cancers - Gastroenterology & Endoscopy News - February 25th, 2025 [February 25th, 2025]
- Virologist Wendy Barclay: Wild avian viruses are mixing up their genetics all the time. Its like viral sex on steroids - The Guardian - February 3rd, 2025 [February 3rd, 2025]
- Do you find coffee too bitter? Scientists explain how your genetics and roasting process affect the flavour - Hindustan Times - February 3rd, 2025 [February 3rd, 2025]
- 2025 Illinois Performance Tested Bull Sale prioritizes trusted genetics for herd growth - Morning Ag Clips - - February 3rd, 2025 [February 3rd, 2025]
- Game-Changing Cancer Detection Tool Spots What Others Miss: New Breakthrough from SOPHiA GENETICS - StockTitan - February 3rd, 2025 [February 3rd, 2025]
- Integrative genetics and multiomics analysis reveal mechanisms and therapeutic targets in vitiligo highlighting JAK STAT pathway regulation of CTSS -... - January 23rd, 2025 [January 23rd, 2025]
- deCODE genetics: Complete recombination map of the human-genome, a major step in genetics - Financial Times - January 23rd, 2025 [January 23rd, 2025]
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - Yahoo Finance - January 23rd, 2025 [January 23rd, 2025]
- Bjarni V. Halldorsson and Kari Stefansson, scientists at deCODE genetics, discuss the paper: Complete recombination map of the human-genome, published... - January 23rd, 2025 [January 23rd, 2025]
- Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan - January 23rd, 2025 [January 23rd, 2025]
- Genetics, brain development, and mental health shape teen eating - News-Medical.Net - January 15th, 2025 [January 15th, 2025]
- Building Better Flu Shots Based on Antibody Responses and Genetics - Vax-Before-Travel - January 15th, 2025 [January 15th, 2025]
- Its in the Genes: Weight and Metabolism Determined by Genetics More Than Diet - Cville Right Now - January 15th, 2025 [January 15th, 2025]
- It's in the genes: Weight and metabolism determined by genetics more than diet - Medical Xpress - January 15th, 2025 [January 15th, 2025]
- Trump and Musk are obsessed with genetics but theres no science behind their simplistic views - The Guardian - January 1st, 2025 [January 1st, 2025]
- From Stonehenge's origins to ice age baby genetics how well did you follow this year's top archaeology stories? - Livescience.com - January 1st, 2025 [January 1st, 2025]
- William Thilly, MIT genetics professor who invented Apple Jacks cereal, dies at 79 - The Boston Globe - January 1st, 2025 [January 1st, 2025]
- Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- With 54% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- Using the PERC Database to Gather Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD - Neurology Live - December 23rd, 2024 [December 23rd, 2024]
- Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan - December 23rd, 2024 [December 23rd, 2024]
- Redecan Cannabis Launches New Limited-Edition Genetics and Expands Signature 'Wrapped & Redee' Pre-roll Line for the Holidays - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- Surprising yields, impressive genetics and an early harvest in 2024 Ohio Ag Net - Ohio's Country Journal and Ohio Ag Net - December 9th, 2024 [December 9th, 2024]
- Using music to help people with dementia; supporting breastfeeding radiologists; genetics and Type 2 diabetes; plus other news stories with VUMC... - December 9th, 2024 [December 9th, 2024]
- Genetics and suicideWhats the link? - Genetic Literacy Project - December 9th, 2024 [December 9th, 2024]
- Genetics is all fun and games for a Rochester card game creator - Rochester Post Bulletin - November 28th, 2024 [November 28th, 2024]
- Community engagement conduct for genetics and genomics research: a qualitative study of the experiences and perspectives of key stakeholders in Uganda... - November 28th, 2024 [November 28th, 2024]
- Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics - Nature.com - November 28th, 2024 [November 28th, 2024]
- Texas A&M Researchers Uncover Secrets Of Horse Genetics For Conservation, Breeding - Texas A&M University Today - November 20th, 2024 [November 20th, 2024]
- Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire - November 20th, 2024 [November 20th, 2024]
- Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance - November 20th, 2024 [November 20th, 2024]
- Precision mutational scanning: your multipass to the future of genetics - Nature.com - November 20th, 2024 [November 20th, 2024]
- Advancements of Haploid Technology in Crops: New Horizons in Breeding and Genetics - Frontiers - November 20th, 2024 [November 20th, 2024]
- Toward advances in retinoblastoma genetics in Kenya - Nature.com - November 12th, 2024 [November 12th, 2024]
- CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production - Nature.com - November 12th, 2024 [November 12th, 2024]
- Genetics Play Key Role in Animal Health and Welfare, Aggression and Handling - Farms.com - November 12th, 2024 [November 12th, 2024]
- Episode 174: Rudy Tanzi talks about genetics, aging and the hallmarks of Alzheimers - IHMC - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Pharmaceutical Technology - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - WV News - October 26th, 2024 [October 26th, 2024]
- Faculty of Science | Protecting Canadas number one crop through genetics - UM Today - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo Finance - October 26th, 2024 [October 26th, 2024]
- Opinion | Fascinated by genetics? Where are the peas Trump made to fornicate? - The Washington Post - October 13th, 2024 [October 13th, 2024]
- Dietary restriction can extend lifespan but genetics matters more - Nature.com - October 13th, 2024 [October 13th, 2024]
- 'They have much stronger players' - Bangladesh assistant coach bizarrely blames 'genetics' for lack of six hitters in the team - Sporting News - October 13th, 2024 [October 13th, 2024]
- Medical Moment: Genetics and breast cancer with USA Health Genetic Counselor Cassie Gurganus - AOL - October 13th, 2024 [October 13th, 2024]
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer - Yahoo Finance - October 13th, 2024 [October 13th, 2024]
- An ideologically-based and misleading critique of how modern genetics is taught - Why Evolution Is True - October 13th, 2024 [October 13th, 2024]
- 2024 Mercedes-AMG C63 Review: Bold But Beholden to Its Genetics - Newsweek - October 2nd, 2024 [October 2nd, 2024]
- Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date - GlobeNewswire - October 2nd, 2024 [October 2nd, 2024]
- Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care... - October 2nd, 2024 [October 2nd, 2024]
- The role of genetics in depression | Second Opinion - KCRW - September 23rd, 2024 [September 23rd, 2024]
- Tilapia genetics company Spring Genetics teams up with UK data firm to improve fish welfare - SeafoodSource - September 23rd, 2024 [September 23rd, 2024]
- Picky eating in kids is mostly due to genetics, study says - Motherly Inc. - September 23rd, 2024 [September 23rd, 2024]
- Research Shows That Fussy Eating In Children Is Mainly Influenced By Genetics - RTTNews - September 23rd, 2024 [September 23rd, 2024]
- Genetics colloquium: Chris Hittinger on the genomic making of metabolic niche breadth Sep. 11 - University of WisconsinMadison - September 15th, 2024 [September 15th, 2024]